🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Minimal Correlation but Complementary Diagnostic Utility for Plasma Cell-free RNA and Proteins biorxiv.org/content/10.110… #biorxiv_genomic

I forgot to mention! We're recruiting graduate students to develop the next generation of cancer detection tools. Our lab is ideally located in #Montreal and is affiliated with Centre de recherche du CHUM and École de technologie supérieure ^amazing place to go from innovation ▶️ clinic Apply: tinyurl.com/mwtaesee

Our commentary describing the potential of designed #microbial #consortia for sustainable #waste management and #climate resilience is out! You can check it here sciencedirect.com/science/articl… to the authors Ginevra Giangeri Irini Angelidaki Nikos Kyrpides - Department of Biology – University of Padova DTU-bioenergy Joint Genome Institute

DCVC portfolio company kanvasbio has developed a new spectral lightsheet microscope that surpasses the resolution and spectral capa­bil­i­ties of the best commer­cially available instruments. The tool will allow the company to generate novel, proprietary data about

Our new multi-country study evaluates swab-based molecular tests for #TB, showing strong accuracy using both sputum and tongue swabs. Near point-of-care platforms like MTB Ultima and MiniDock MTB could help enable universal molecular testing. medrxiv.org/content/10.110…

This was a fun review to write with Uschi Symmons on the conceptual underpinnings of single cell biology!

So excited to be featured in Medscape in their article on frontiers in 3D bioprinting (medscape.com/viewarticle/hu…) Cornell BME Cornell Engineering #bioprinting #TissueEngineering

Please RETWEET! 2 postdocs (one chemical biologist, one RNA biologist) and multiple PhD positions are available at #KwokLab, City University of Hong Kong. We work on #RNA, #Gquadruplex, #aptamer , #peptide, #Biosensor and more! See kitkwok.com . PM if interested.

Cell‑free DNA testing has gone from concept to standard of care in heart transplantation! 🔗 GenomeWeb: shorturl.at/KybbI I am proud that our 2014 Science Translational Medicine study helped lay the groundwork 🙌 doi.org/10.1126/scitra… #LiquidBiopsy #ScienceForTheWin 🎯

I'm thrilled to share our new #bioRxiv preprint from ⁦Junyue⁩ lab at ⁦Rockefeller University⁩! We present PerturbFate, a high-throughput single-cell CRISPR platform profiling nascent/pre-existing RNA, steady-state RNA & chromatin accessibility. biorxiv.org/content/10.110…

Under development by Cornell University researcher James Antaki for over 30 years, PediaFlow has the potential to save the lives of tens of thousands of babies with heart defects and to allow newborns to go home with their families while awaiting surgery. youtube.com/watch?v=a7aUBv…

Today, in collaboration w/ colleagues at the Institute of Science and Technology Austria (ISTA), we report the first-ever method for using light microscopy to comprehensively map all the neurons & their connections in a block of mouse brain tissue. More →goo.gle/4maUNUs

Terrific seeing Lux Capital stand up to support biomedical research in America. I hope that more venture firms and philanthropies will follow their lead!

Cornell ranks among NAI's top 100 list for US patents, showcasing innovations with real-world impact! From energy-saving semiconductors to targeted cancer therapies, Cornell University innovations are moving from lab to market. Learn more about the ranking bit.ly/3GVsuJw

This is an incredible progress story An aggressive type of cancer (Philadelphia chromosome–positive acute lymphoblastic leukemia) used to carry a dismal prognosis, with 50% of patients dying in a year New therapies have transformed it to a cancer that most people are cured of

A new material developed Cornell Engineering could significantly improve the delivery and effectiveness of mRNA vaccines – used to fight COVID-19 – by replacing a commonly used ingredient that may trigger unwanted immune responses in some. Nature Materials NIH news.cornell.edu/stories/2025/0…

Check out this new work in Nature Materials by my brilliant Cornell BME colleague Shaoyi Jiang: zwitterionic lipid nanoparticles turbo-charge mRNA delivery 👉 nature.com/articles/s4156…

A new material developed by Shaoyi Jiang and collaborators could significantly improve the delivery and effectiveness of mRNA vaccines – used to fight COVID-19 – by replacing a commonly used ingredient that may trigger unwanted immune responses in some. Nature Materials NIH

Harnessing the power of the microbiome: Kanvas Biosciences was launched through Cornell University’s Center for Life Science Ventures, with technology licensed through the Center for Technology Licensing (Center for Technology Licensing at Cornell). Cornell BME Cornell Grad School news.cornell.edu/stories/2025/0…

From Cornell University lab to clinical trials: Kanvas Biosciences, a Cornell-licensed startup, is turning microbiome research into cancer-fighting therapies. Co-founded by Hao Shi, PhD ’20, its synthetic stool drug is heading to human trials. Learn more👇 #CornellResearch #CornellStartups